Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Account Payables (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Change in Account Payables for 6 consecutive years, with -$1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 366.24% year-over-year to -$1.0 million, compared with a TTM value of -$2.3 million through Sep 2025, up 5.05%, and an annual FY2024 reading of $898000.0, up 126.58% over the prior year.
  • Change in Account Payables was -$1.0 million for Q3 2025 at Barinthus Biotherapeutics, down from $342000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.3 million in Q3 2023 and bottomed at -$3.8 million in Q4 2023.
  • Average Change in Account Payables over 5 years is -$353789.5, with a median of -$524000.0 recorded in 2024.
  • The sharpest move saw Change in Account Payables surged 975.44% in 2022, then crashed 480.26% in 2023.
  • Year by year, Change in Account Payables stood at -$114000.0 in 2021, then soared by 975.44% to $998000.0 in 2022, then plummeted by 480.26% to -$3.8 million in 2023, then soared by 87.88% to -$460000.0 in 2024, then plummeted by 126.3% to -$1.0 million in 2025.
  • Business Quant data shows Change in Account Payables for BRNS at -$1.0 million in Q3 2025, $342000.0 in Q2 2025, and -$1.2 million in Q1 2025.